论文部分内容阅读
目的探讨低分子肝素联合葛根素治疗不稳定型心绞痛的疗效和安全性。方法将128例不稳定型心绞痛病人随机分为对照组(常规治疗组)和治疗组(常规治疗加低分子肝素联合葛根素),观察治疗前后每日心绞痛发作次数,持续时间,常规12导联心电图ST—T段改善情况,血小板计数,凝血酶原时间,部分凝血活酶时间(APTT),冠心病事件发生情况和出血并发症等。结果治疗组64例,总有效率95.4%,对照组64例,总有效率76.5%。结论低分子肝素联合葛根素治疗不稳定型心绞痛从疗效、冠心病事件发生、安全性方面优于对照组。
Objective To investigate the efficacy and safety of low molecular weight heparin combined with puerarin in the treatment of unstable angina pectoris. Methods 128 patients with unstable angina were randomly divided into control group (conventional treatment group) and treatment group (conventional treatment combined with low molecular weight heparin and puerarin), the number of daily angina pectoris before and after treatment, duration, routine 12-lead ECG ST-T segment improvement, platelet count, prothrombin time, partial thromboplastin time (APTT), coronary heart disease events and bleeding complications. Results 64 cases of treatment group, the total effective rate was 95.4%, 64 cases in the control group, the total effective rate was 76.5%. Conclusion Low molecular weight heparin combined with puerarin in the treatment of unstable angina pectoris is superior to the control group in terms of curative effect, occurrence and safety of coronary heart disease.